secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001493152-26-011222
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO
-----------------------------------------------------------------------

- CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.
- Board appointed Gary Stetz as interim CEO and director; Vincent LoPriore as Executive Chairman.
- Sireesh Appajosyula and Chase LoPriore also appointed to the board of directors.
- No family relationships or arrangements between new appointees and other officers disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226011222/0001493152-26-011222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226011222/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-011222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer